Aspire Biopharma获得Nasdaq的延伸,以修补合规问题和重组,推动市场发展,2025年12月15日。 Aspire Biopharma gets Nasdaq extension to fix compliance issues and restructure, moving markets Dec. 15, 2025.

Aspire Biopharma(ASBP)已收到Nasdaq的延期,以重新遵守列名要求,使其能够留在交易所。 Aspire Biopharma (ASBP) has received a Nasdaq extension to regain compliance with listing requirements, allowing it to stay on the exchange. 该公司必须在2026年1月30日和2月17日之前分别达到投标价格和股权规则,并将于2025年12月15日起将其股票从Nasdaq全球选择市场转移到Nasdaq资本市场,不造成交易中断。 The company must meet bid price and equity rules by January 30 and February 17, 2026, respectively, and will move its stock from the Nasdaq Global Select Market to the Nasdaq Capital Market effective December 15, 2025, with no trading disruption. 延长期限支持其重组资产负债表和创造长期股东价值的计划。 The extension supports its plan to restructure its balance sheet and create long-term shareholder value. 艾斯普尔开发了一种语言下药物递送技术,旨在通过绕过消化系统,更快,更有效地递送药物,并可用于各种治疗和补充剂. Aspire develops a sublingual drug delivery technology aimed at faster, more effective medication delivery by bypassing the digestive system, with applications across various therapeutics and supplements. 前瞻性说明面临风险和不确定性。 Forward-looking statements are subject to risks and uncertainties.